Lakeshore Biopharma (LSB) Competitors $2.42 -0.04 (-1.43%) Closing price 03:58 PM EasternExtended Trading$2.41 0.00 (-0.21%) As of 04:05 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisChartCompetitorsEarningsFinancialsHeadlinesOwnershipSEC FilingsShort InterestTrendsBuy This Stock LSB vs. FATE, VXRT, ANIX, SNTI, BDTX, ATOS, OCX, ADVM, KYTX, and ORMPShould you be buying Lakeshore Biopharma stock or one of its competitors? The main competitors of Lakeshore Biopharma include Fate Therapeutics (FATE), Vaxart (VXRT), Anixa Biosciences (ANIX), Senti Biosciences (SNTI), Black Diamond Therapeutics (BDTX), Atossa Therapeutics (ATOS), OncoCyte (OCX), Adverum Biotechnologies (ADVM), Kyverna Therapeutics (KYTX), and Oramed Pharmaceuticals (ORMP). These companies are all part of the "pharmaceutical products" industry. Lakeshore Biopharma vs. Fate Therapeutics Vaxart Anixa Biosciences Senti Biosciences Black Diamond Therapeutics Atossa Therapeutics OncoCyte Adverum Biotechnologies Kyverna Therapeutics Oramed Pharmaceuticals Fate Therapeutics (NASDAQ:FATE) and Lakeshore Biopharma (NASDAQ:LSB) are both small-cap medical companies, but which is the better business? We will compare the two businesses based on the strength of their community ranking, risk, analyst recommendations, earnings, media sentiment, dividends, profitability, institutional ownership and valuation. Do insiders and institutionals hold more shares of FATE or LSB? 97.5% of Fate Therapeutics shares are held by institutional investors. Comparatively, 52.6% of Lakeshore Biopharma shares are held by institutional investors. 5.0% of Fate Therapeutics shares are held by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock will outperform the market over the long term. Which has more volatility and risk, FATE or LSB? Fate Therapeutics has a beta of 2.26, suggesting that its share price is 126% more volatile than the S&P 500. Comparatively, Lakeshore Biopharma has a beta of 0.68, suggesting that its share price is 32% less volatile than the S&P 500. Is FATE or LSB more profitable? Lakeshore Biopharma has a net margin of 0.00% compared to Fate Therapeutics' net margin of -1,325.43%. Lakeshore Biopharma's return on equity of 0.00% beat Fate Therapeutics' return on equity.Company Net Margins Return on Equity Return on Assets Fate Therapeutics-1,325.43% -45.88% -33.95% Lakeshore Biopharma N/A N/A N/A Does the MarketBeat Community prefer FATE or LSB? Fate Therapeutics received 480 more outperform votes than Lakeshore Biopharma when rated by MarketBeat users. CompanyUnderperformOutperformFate TherapeuticsOutperform Votes48067.51% Underperform Votes23132.49% Lakeshore BiopharmaN/AN/A Which has stronger valuation and earnings, FATE or LSB? Lakeshore Biopharma has higher revenue and earnings than Fate Therapeutics. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioFate Therapeutics$13.63M6.51-$160.93M-$1.64-0.47Lakeshore Biopharma$672.27M0.03-$61.09MN/AN/A Do analysts rate FATE or LSB? Fate Therapeutics currently has a consensus price target of $5.43, suggesting a potential upside of 601.37%. Given Fate Therapeutics' stronger consensus rating and higher probable upside, equities research analysts clearly believe Fate Therapeutics is more favorable than Lakeshore Biopharma.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Fate Therapeutics 0 Sell rating(s) 7 Hold rating(s) 2 Buy rating(s) 0 Strong Buy rating(s) 2.22Lakeshore Biopharma 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00 Does the media favor FATE or LSB? In the previous week, Fate Therapeutics and Fate Therapeutics both had 1 articles in the media. Fate Therapeutics' average media sentiment score of 1.89 beat Lakeshore Biopharma's score of 1.87 indicating that Fate Therapeutics is being referred to more favorably in the media. Company Overall Sentiment Fate Therapeutics Very Positive Lakeshore Biopharma Very Positive SummaryFate Therapeutics beats Lakeshore Biopharma on 9 of the 14 factors compared between the two stocks. Remove Ads Get Lakeshore Biopharma News Delivered to You Automatically Sign up to receive the latest news and ratings for LSB and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart LSB vs. The Competition Export to ExcelMetricLakeshore BiopharmaPharmaceutical IndustryMedical SectorNASDAQ ExchangeMarket Cap$22.47M$6.75B$5.55B$7.86BDividend YieldN/A2.81%5.35%4.05%P/E RatioN/A7.1323.4918.67Price / Sales0.03199.71367.9687.39Price / CashN/A65.6738.1634.64Price / Book0.275.966.634.09Net Income-$61.09M$142.11M$3.20B$246.93M7 Day Performance-12.97%-9.40%-6.41%-3.77%1 Month Performance9.03%-12.59%-1.54%-6.73%1 Year PerformanceN/A-15.13%7.23%-1.87% Lakeshore Biopharma Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)LSBLakeshore Biopharma1.5081 of 5 stars$2.42-1.4%N/AN/A$22.47M$672.27M0.00773Positive NewsGap UpFATEFate Therapeutics3.8738 of 5 stars$0.79-0.1%$5.43+588.0%-89.2%$90.19M$13.63M-0.48550Positive NewsVXRTVaxart2.2337 of 5 stars$0.39-4.2%$3.00+669.2%-68.5%$88.90M$28.70M-0.95120Analyst RevisionANIXAnixa Biosciences3.1283 of 5 stars$2.70-5.6%$9.00+233.5%-8.3%$87.09M$210,000.00-6.945Gap UpSNTISenti Biosciences3.6771 of 5 stars$3.35-2.5%$10.00+199.0%-10.9%$86.98M$2.56M-0.214Positive NewsGap DownBDTXBlack Diamond Therapeutics3.3571 of 5 stars$1.54-1.0%$14.60+851.1%-69.4%$86.98MN/A-1.1590Positive NewsATOSAtossa Therapeutics1.8889 of 5 stars$0.67-0.7%$7.00+947.9%-62.6%$86.67MN/A-3.058Earnings ReportOCXOncoCyte2.5529 of 5 stars$3.02-1.3%$4.56+51.1%+4.4%$86.40M$1.88M-0.69120Analyst ForecastShort Interest ↑News CoverageGap UpADVMAdverum Biotechnologies4.4055 of 5 stars$4.14-5.3%$27.83+572.3%-69.1%$86.12M$1M-0.69190Positive NewsGap DownKYTXKyverna Therapeutics1.5773 of 5 stars$2.00+3.4%$18.67+835.7%-92.2%$85.70M$7.03M-0.5796Earnings ReportAnalyst ForecastNews CoverageORMPOramed Pharmaceuticals1.76 of 5 stars$2.10-1.9%N/A-26.7%$84.66M$1.34M19.0910Earnings ReportUpcoming EarningsPositive News Remove Ads Related Companies and Tools Related Companies Fate Therapeutics Competitors Vaxart Competitors Anixa Biosciences Competitors Senti Biosciences Competitors Black Diamond Therapeutics Competitors Atossa Therapeutics Competitors OncoCyte Competitors Adverum Biotechnologies Competitors Kyverna Therapeutics Competitors Oramed Pharmaceuticals Competitors Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:LSB) was last updated on 4/1/2025 by MarketBeat.com Staff From Our PartnersTrump’s Secret WeaponHave you looked at the stock market recently? Millions of investors are scrambling trying to figure out what's...American Alternative | SponsoredA market crash is coming—here’s whenThe stock market cycle I've used to identify the most likely day of the next market crash is the exact same in...Chaikin Analytics | SponsoredElon Musk Confirms: Tesla’s Optimus is Replacing Workers… and Heading to MarsMusk confirmed that SpaceX's Starship will carry Optimus to Mars in 2026 as part of an autonomous mission to h...InvestorPlace | SponsoredTrump Allies Confirm Exec Order 14024 Triggers Dollar CollapseExecutive Order 14024 is paving the way for irreversible damage to the dollar's value—threatening your wealth,...Priority Gold | SponsoredRetirement Nightmare? It’s Already Happening.The market is on edge. Every day, another company slashes its dividend, leaving investors scrambling. Intel...Investors Alley | SponsoredNew “Trump” currency proposed in DCA former U.S. Presidential Advisor has come forward with a stern warning to investors: “Get out of tech, no...Paradigm Press | Sponsored10X Bigger than AI, quantum, EVs, crypto, and robotics combined?World Economic Forum: "Arguably the Most Exciting Human Discovery Since Fire" Sam Altman, Bill Gates, and M...Stansberry Research | SponsoredIs Fort Knox Hiding Less Gold Than We Think? Find Out What That Means for YouWith gold prices recently soaring to record highs over $3,000 an ounce, and central banks rushing to accumulat...The Oxford Club | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Lakeshore Biopharma Co., Ltd. Please log in to your account or sign up in order to add this asset to your watchlist. Share Lakeshore Biopharma With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
